Introduction {#S1}
============

Cancer progression is usually studied cross-sectionally, comparing lesions obtained from different patients, excised at various stages. By combining these snapshots, the natural history of the disease can be indirectly reconstructed. In contrast, the preferable longitudinal analysis of sequential lesions in the same patients is usually not feasible, especially difficult to perform in rapidly progressing cancers, such as melanoma, and particularly challenging when analyzing disease progression in metastases ([@R3]; [@R16]; [@R21]).

However, the limited number of such longitudinal studies leaves several questions open. First, cross-sectional studies do not allow an estimate of the extent in which patient-specific traits remain stable over time. Therefore, it is difficult to assess the stability of such patient-specific traits over time, which is a question of basic importance in personalized cancer therapy ([@R9]; [@R10]; [@R22]).

In addition, with cross-sectional analyses it is impossible to test, whether late disease development follows a pattern of sequential somatic microevolution, or subsequent metastases represent individual buddings from a stable set of cancer progenitors creating independently established new metastatic lesions ([@R27]; [@R35]).

Finally, it is difficult to quantify whether sequential steps are involved in late stage progression, and estimate whether consistent changes are required for the late progression of melanoma from a metastatic phase that progresses slowly, to a rapid evolution in the declining phase of one patient's life.

Studying longitudinally several recurrent melanoma metastases of a rare collection of eight individuals who developed multiple recurrences over a period of years (see [Table S1](#SD1){ref-type="supplementary-material"}), we sought a better understanding of the above questions. This study is a follow up from a previous longitudinal study of a single case ([@R27]; [@R35]) focusing on traits remaining stable and changes repeated consistently among multiple developing recurrent metastases of several melanoma patients. To our best knowledge, these questions have not yet been analyzed by others.

Results {#S2}
=======

Long term metastatic melanoma is consistent with canonical melanoma genomics {#S3}
----------------------------------------------------------------------------

Since the cases with multiple recurrent metastases studied here differ behaviorally from classic metastatic melanoma due to their unusually protracted course, we first evaluated whether the cell lines derived from these unusual cases would differ markedly from typical cases of melanoma as published by others.

Array comparative genomic hybridization (aCGH) confirmed that the chromosomal distribution of copy number (CN) alterations (CNAs) prominently observed here are in line with previous observations ([Fig. 1a](#F1){ref-type="fig"}) ([@R14]; [@R26]; [@R31]; [@R32]). Also, at the individual gene level, most genes were affected by copy number gains and losses in accordance with others' reports ([@R7]; [@R14]; [@R24]; [@R25]; [@R30]) ([Fig. 1b](#F1){ref-type="fig"}, see full data set in [Table S2](#SD1){ref-type="supplementary-material"}).

Finally, similar to others' reports, we also found that a correlation between CN and gene expression (GX) data is present, but limited in advanced cancer ([@R1]; [@R27]; [@R31]). Among 4,340 genes eligible for analysis, 2,766 correlated weakly (Pearson's correlation R\<0.3, p\<0.05, false discovery rate (FDR) 0.05) and 272 strongly (R\<0.5, p\<0.05, FDR 0.01) in CN and GX (see [Figure S1](#SD1){ref-type="supplementary-material"}).

Taken together, this dataset was representative of typical characteristics of metastatic melanoma genomics, as reported in the literature ([@R1]; [@R14]; [@R26]; [@R27]; [@R31]; [@R32]).

Advanced melanoma retains case-specific fingerprints after years of disease progression {#S4}
---------------------------------------------------------------------------------------

Following a rare case of metastatic melanoma that recurred several times over a decade, we previously observed that in spite of the stochastic and selective forces affecting its genome, stable characteristics prevailed to the point that recurrent lesions derived from this patient clustered away from heterologous randomly collected cases ([@R27]; [@R35]). This patient-specific stability, if shared by other cases of advanced melanoma, could have fundamental implications for personalized cancer therapy. Thus, in this study, we first analyzed whether the previous observations could be generalized to a larger set of patients.

First we compared CNA and GX patterns on a global genomic scale among cell lines from the eight patients with multiple recurrences. Multidimensional scaling (MDS), a computational method enabling visualization of sample relatedness within large scale genetic data demonstrated that even after years, recurrent metastases of a given patient remained closely related, keeping clear distance from others' metastases ([Fig. 2a and 2c](#F2){ref-type="fig"}). By comparing all metastases in all possible pairs (325 pairs total), we found that MDS distances between subsequent metastases (estimates of sample relatedness) of the same patient were significantly shorter than those between metastases of different patients ([Fig. 2b and 2d](#F2){ref-type="fig"}). This finding held true whether CNA or GX data were compared.

Stable patient-specific traits include genes of relevance to melanoma biology {#S5}
-----------------------------------------------------------------------------

We next searched for genomic aberrations typically specific to a given patient. We found that stable case-specific CNAs occurred in chromosomes 1, 5, 13, and 19 ([Fig. 3a](#F3){ref-type="fig"} One Way Analysis of variance (ANOVA), p\<0.05, FDR\<0.001, see [Table S3](#SD1){ref-type="supplementary-material"} for details). Similarly, 925 genes were found to have stable, patient-specific expression; 61 among them could be categorized functionally as melanoma-related by the Ingenuity Pathway Analysis database ([Fig. 3b](#F3){ref-type="fig"}, One-Way ANOVA, p\<0.05, FDR\<0.05). The latter included several genes with known tumorigenic properties supporting autonomous proliferation (*KIT, MYC, CDK2, RBL2*), controlling genomic stability (*BRCA1*), apoptosis and cell survival (*TP53BP2, CASP8, TEP1*), adhesion and motility (*CDH1, ITGA4*), invasiveness, matrix remodeling (*MMP15, MMP19*), angiogenesis (*ANGPT1, EGF*), modulation of anti-tumor immunity, (large clusters of major histocompatibility complex class I and II transcripts, the latter correlating with *CIITA* expression) and several melanoma antigens (*MAGE-A1, -A4, -A9, -B2, -C2*). This observation suggests that genes highly relevant to melanoma progression retain stable patient-specific expression levels over long periods of time ([Fig. 3b](#F3){ref-type="fig"}).

Notably among all possible patient-to-patient comparisons (28 pairwise comparisons involving 8 patients), 37 genes demonstrated patient-specific expression pattern with significant differences among patients and an at least two-fold change in \>70% of all pair wise comparisons. These included *MAGE-A4, -B2, -C2, BAGE-2*, and *KIT* (see [Table S4](#SD1){ref-type="supplementary-material"}). To further test these results, we analyzed KIT protein levels by flow cytometry in the investigated cell lines. Our analysis disclosed that although KIT expression is frequently affected by post-transcriptional regulation, KIT protein levels remain consistent throughout multiple recurrences of individual patients, and whenever expressed, correlate well with mRNA data ([Fig. S2](#SD1){ref-type="supplementary-material"}). Taken together, these observations suggest that genes relevant to melanoma immunology and melanoma cell biology are expressed stably within a given patient, and may, in turn, be responsible for behavioral differences among individual cancers.

Lack of evidence for convergent evolution and consistent changes among patients over time {#S6}
-----------------------------------------------------------------------------------------

Next, we asked whether subsequent metastases from different patients progressively converge to reach a terminal, potentially lethal "hyper-aggressive" status. This would imply that on average, early (e.g. first) metastases of individual patients would be more different, more distant from each other than late (e.g. the last) metastases of the same individuals. MDS genomic distances demonstrate that this is not the case ([Fig. 4a and 4b](#F4){ref-type="fig"}), neither at the CN or at the GX level.

To corroborate this finding, we next attempted to identify consistent CN or GX changes that might represent a recurrent theme in the transition from earlier to later metastases in a given patient. However, statistical analysis was unable to identify changes in CN alterations or GX patterns that constitute consistent trends in subsequent recurrences of metastatic melanoma, (Two-Way RM ANOVA p\<0.05 FDR 0.05). First, an analysis of all recurrent metastases inclusive of patient identity and lesion sequence revealed no consistent changes between subsequent metastases. Next, since patients with large numbers of recurrences dominate the analysis in such a pair wise comparison, we decreased or eliminated differences in per-patient sample sizes. To this end, we first replaced multiple synchronous metastases with a single averaged value for each parameter tested (p\<0.05 FDR 0.05). Also, in a separate analysis we limited the evaluated cases to 3 randomly selected samples per patient (p\<0.05 FDR 0.05). No consistent changes were found by either analysis. Next, assuming that the first and last available lesions in a given patient were most distant genetically, we restricted the analysis to these extreme pairs; but again, a pair wise analysis including patient identity failed to identify statistically significant differences (p\<0.05 FDR 0.05). Finally, hypothesizing that the last, supposedly most advanced, fatal lesion in a given patient might be different from earlier ones, we compared the latter with the former (p\<0.05 FDR 0.05), again without observing consistent differences. Taken together, no consistent progression patterns could be observed between subsequent metastases, either at the DNA copy number or RNA gene expression level, regardless of the approach used for sample selection and grouping before statistical analysis.

In line with this observation, comparison of the first metastasis from a given patient with his subsequent ones demonstrated that the latter are not necessarily drifting progressively further from the original one ([Fig. 4c and 4d](#F4){ref-type="fig"}). Rather, the data suggest a stochastic drift among subsequent recurrent metastases.

We also tested whether multiple cycles of phenotype switching between proposed invasive and proliferative phenotypes ([@R13]) could explain a seemingly stochastic drifting of recurrent melanoma metastases. We found that this model may provide partial explanation for our observations, as key genes of the two phenotypes were expressed in an alternating fashion, and the two phenotypes seemed to change frequently back and forth through the recurrences of most (e.g. patients B, C, D, F, G), although certainly not all patients (e.g. patients A and E, [Fig. S3](#SD1){ref-type="supplementary-material"}).

The fate of homozygous deletions does not support cumulative changes in the evolution of melanoma {#S7}
-------------------------------------------------------------------------------------------------

Since no step-wise evolutionary pattern could be discerned, we next asked whether recurrent metastases from the same patient descend sequentially from one another, i.e. if they acquire new mutations in a cumulative fashion. To this end, we followed the fate of common *BRAF, NRAS* mutations ([@R4]) and homozygous deletions (−/−) in subsequent recurrent metastases. Unfortunately, *BRAF* and *NRAS* status turned out to be uninformative in this regard, because as frequently observed in melanoma, all recurrent melanomas analyzed were BRAFV600E mutated and NRAS wild type throughout (not shown). Next we analyzed the fate of homozygous deletions (−/−) that are thought to be irreversible since no known mechanisms for structural restoration of these alterations have been described. Based on this, we assumed that if subsequent recurrent metastases of the same patient show reversions of homozygous deletions, they cannot sequentially descend from each other.

A total of 33 contiguous homozygous deletions were found affecting the *CDKN2A/CDKN2B* region, various interferon genes, *B2M*, major histocompatibility complex genes, etc. Out of these, 25 deletions were eligible for analysis as they emerged in a metastasis for which there was at least a subsequent metastasis to evaluate ([Fig. 5b](#F5){ref-type="fig"}). Out of 25 eligible homozygous deletions, 15 (60%) appeared to be reverted in a given patient's disease history, suggesting that in subsequent metastases of recurrent melanoma, new mutations are not acquired in a cumulative fashion, and hence, recurrent metastases do not descend from each other ([Fig. 5b](#F5){ref-type="fig"}).

Recurrent melanomas show hints of slower growth, but more frequent metastasis formation {#S8}
---------------------------------------------------------------------------------------

In initial MDS analyses, cancer cells from patients with recurrent long term metastatic disease were hardly discernible from those from sporadically excised, melanoma cases ([Fig. 2a and 2c](#F2){ref-type="fig"}). Nevertheless, we identified a set of 177 genes differentially expressed between the two phenotypes, which is a very small number compared to patient-to-patient differences, 8 of which were melanoma-related. Interestingly, these genes hint to slower tumor growth (retained *CDKN1A* and *ANAPC* expression), higher sensitivity to immune- or therapy-mediated eradication (higher *FAS* but lower levels of *MGMT* expression), and higher pro-metastatic tendency (elevated levels of *ALCAM*, [Fig. S4](#SD1){ref-type="supplementary-material"}).

Discussion {#S9}
==========

This study analyzes a specific time point in the natural history of cancer when advanced disease of an indolent nature turns into an aggressive and lethal stage. We studied the genetic profile of melanoma cell lines derived from sequentially excised metastases in unusual cases when the metastatic process followed a protracted course. Although the use of cell lines has significant limitations, we observed that early passage cell lines maintain stable genetic traits *in vitro* that relate to the *in vivo* phenotype of parental tumors ([@R31]). Nevertheless, our samples clearly do not equal whole tumors, and these cases may have represented a special subset of melanoma, as well. First, these recurrent melanomas displayed CDK2NA, PTEN, and BRAF copy number aberrations more frequently than average cases ([@R12]; [@R15]). In addition, all 26 metastases of the analyzed 8 patients carried BRAFV600E, but displayed wild type NRAS. Conservation of BRAF mutation status across metastases is in line with others' observations ([@R23]). However, this particular BRAF/NRAS pattern is typical for melanomas arising in intermittently sun-exposed areas ([@R4]), affects cell proliferation rate ([@R18]), prognosis ([@R19]), treatment of choice, and in this latter context, also BRAF copy numbers ([@R30]).

Keeping these limitations in mind, our data suggest that key elements of the framework of recurrent metastatic melanomas remain stable with time; since such stability was observed in 8 out of 8 patients, it possibly represents the rule rather than the exception. This is a remarkable finding considering that at the same time, our data also support the accepted view of late stage cancer evolution being a highly dynamic process, also shown recently by others ([@R6]; [@R28]) using indirect computational inference; however, this study uniquely provides direct evidence by studying serially asynchronous metastases over a long period.

Our findings suggest that individuality is maintained throughout a non-directional drift that does not follow a clearly linear progression, with each metastatic signature stemming *de novo* from a stable progenitor entity. Moreover, there was no sign of a convergent evolution in advanced late stage melanoma toward the creation of a convergent lethal phenotype, and recurrent metastases did not seem to be each other's clonal descendants, or accumulate incremental changes, which is in line with others' recently published observations ([@R4]).

On the other hand, the observation that stable expression of cancer/testis antigens and the *c-kit* proto-oncogene across multiple recurrences of melanoma implies that, late stage melanoma is capable of displaying stable, case-specific differences directly affecting markers determining vulnerability to novel forms of immunological or small molecule biotherapy ([@R8]; [@R33]; [@R34]).

It remains to be clarified to what extent these observations are attributable to the effects of clonal heterogeneity ([@R6]; [@R28]), circulating tumor cells ([@R20]; [@R36]) that may remain dormant for years and reset the evolutionary clock upon their reactivation, multiple events of phenotype switching ([@R5]; [@R13]), or persistent cancer stem cells opening multiple alternative ways to cancer evolution with each individual recurrence ([@R17]; [@R29]). Larger and more comprehensive studies involving genome-wide DNA sequencing, epigenetic and proteomic analyses, analyzing patients with average survival times, and resected whole tumors instead of cell lines, are strongly warranted to clarify these questions and confirm the applicability of our findings to usual cases of advanced melanoma.

Materials and Methods {#S10}
=====================

Patients and samples {#S11}
--------------------

Twenty-six recurrent melanoma metastases were surgically isolated from 8 patients experiencing relapse after one or more successful treatment intervention(s) with no signs of residual disease. Recurrent metastases from different tissues appeared in periods spanning 10--148 months with 8--101 months between recurrences (see [Table S1](#SD1){ref-type="supplementary-material"} for all data regarding samples, patients, treatments and disease history). Patients received therapy and underwent surgery at the Surgery Branch of the National Cancer Institute, National Institutes of Health, USA, or at the Centro di Riferimento Oncologico (Italian National Cancer Institute) in Aviano, Italy. Patients were treated and samples obtained after signing written informed consent approved by each institute's review board, and in accordance with the Declaration of Helsinki Principles. From all lesions, stable cell cultures were established and maintained at the Department of Transfusion Medicine, Clinical Center, National Institutes of Health for at least eight passages. Patients experiencing recurrent metastases were labeled with capital letters; "A", "B", "C", etc., their subsequent metastases as "A/1", "A/2", "B/1", "B/2", etc., while synchronous metastases in a given patient were labeled as "A/1a", "A/1b" etc. All recurrent melanoma metastases analyzed appeared after a single primary tumor. Another 22 melanoma cell lines isolated and maintained as above were expanded from melanoma patients with rapid disease course, for whom only one metastasis was available. As no extended follow up was possible in these cases, the cell lines are considered representative of random time points in the natural course of metastatic melanoma. These cell lines were labeled with Arabic numbers, as "1", "2", "3", etc.

DNA Isolation {#S12}
-------------

Total genomic DNA of cell lines was isolated using the QuickGene DNA whole blood kit S and a QuickGene-810 Nucleic Acid Isolation System (Fujifilm, Tokyo, Japan).

HLA-Typing {#S13}
----------

To exclude accidental cross-contamination of samples, low resolution HLA-typing was performed at the HLA Laboratory, Laboratory Services Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health.

BRAF and NRAS genotyping {#S14}
------------------------

PCR was performed from 50 ng genomic DNA using the HotStarTaq Master Mix Kit (Qiagen, Valencia, CA) and the following primers: BRAF exon 15 forward: 5'-TCATAATGCTTGCTCTGATAGGA-3' BRAF exon 15 reverse: 5'-GGCCAAAAATTTAATCAGTGGA-3', NRAS exon 2 forward: 5'-ATAGCATTGCATTCCCTGTG-3' NRAS exon 2 reverse: 5'-CACAAAGATCATCCTTTCAGAGA-3'. PCR products were labeled using a Big Dye terminator kit v3.1 (Life Technologies, Carlsbad, CA). Sequencing was performed using a 3730 Genetic Analyzer (Applied Biosystems) and analyzed by Sequencher software (Gene Codes, Ann Arbor, MI).

Array Comparative Genome Hybridization (aCGH) {#S15}
---------------------------------------------

All aCGH studies were performed using Agilent's oligo aCGH platform. Briefly, 1 µg of genomic DNA per sample was directly labeled with a Genomic DNA Enzymatic Labeling Kit, prepared for hybridization with help of an Oligo aCGH Hybridization Kit, and hybridized to 105K Human Genome CGH 105A Oligo Microarrays. Arrays were washed with Oligo aCGH Wash Buffers and scanned in a High-Resolution Microarray Scanner (all from Agilent, Santa Clara, CA). Data were deposited in the GEO public database under GSE38187.

RNA Isolation {#S16}
-------------

Total RNA was isolated using Qiagen's RNEasy Mini Kit, following standard protocol.

Gene expression microarray {#S17}
--------------------------

For expression array studies, the Affymetrix Gene Array System was utilized. Briefly, 250 ng total RNA per sample was amplified using a WT expression kit. Next, cDNA was labeled with help of a GeneChip WT Terminal Label and Control Reactions kit. Samples were then prepared for hybridization using the GeneChip Hyb Wash and Stain Kit and loaded to Human Gene ST 1.0 Arrays. Arrays were washed, PE-labeled on a GeneChip Fluidics Station 450, and loaded into a GeneChip Scanner 3000 7G with autoloader for scanning (all from Affymetrix, Santa Clara, CA). Data were submitted to GEO and made publicly available under accession GSE38187.

Microarray data analysis {#S18}
------------------------

Agilent aCGH microarray data were imported into the Partek Genomics Suite software (Partek, St. Louis, Missouri), quantile normalized and pre-processed using a built-in chromosomal segmentation algorithm ([@R11]). Individual chromosomal segments were defined as continuous regions covered by at least 10 consecutive microarray probes, a significant (p\<0.001) and considerable (\>0.3 copies on average) difference between the CN of the given segment and neighboring segments, accepting an error rate of less than +/− 0.3 copies. Segmented genomes were subjected to Multidimensional Scaling (MDS) to describe inter-sample relationships. Partek's One-Way and Two-Way RM ANOVA analyses were performed on segment CNs to identify CNAs different between individual patients, CNAs consistently changed in consecutive metastases of the same patient, and CNAs between recurrent and random cancer samples. To avoid over-estimation of patient-to-patient differences in CNA studies analyzing a mixed-gender group of patients, X and Y chromosome-related data were excluded from all such analyses. Significant differences were identified with a nominal p\<0.05 and were corrected with FDR of \<0.05. Homozygous deletions (−/−) were identified as segments with CN\<0.4 at an error rate of \<+/− 0.3 copies.

Affymetrix gene expression data were imported to Partek Genomic Suite, quantile normalized and batch-corrected using Distance-Weighted-Discrimination, as described elsewhere ([@R2]). MDS, One-Way and Two-Way RM ANOVA analyses were performed as above. CN and GX data were integrated and analyzed with help of Partek Genomic Suite. Genes whose expression levels were found to be affected by CNAs were identified by computing Pearson's correlation between CN and GX values. A Pearson's correlation of R\>0.3 with \<p0.05 and FDR 0.05 was accepted as proof for CAN-affected gene expression.

Flow cytometry {#S19}
--------------

Cells were harvested non-enzymatically using Cellstripper (Corning, Manassas, VA), and stained with LIVE/DEAD Kit (Life Technologies, Carlsbad, CA), anti-CD117(KIT)-APC (BD Biosciences, San Jose, CA), or isotype controls. Data analysis was performed using a MACSQuant Analyser (Miltenyi Biotec, Germany) and FlowJo (TreeStar).
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![Description and basic characterization of the analyzed sample set by integrated copy number and gene expression analysis\
Panel a) shows frequency and spatial distribution of autosomal CN aberrations in the analyzed melanoma sample set. Panel b) displays combined distribution analysis of CN gains and losses affecting key melanoma genes, and also their distribution between various, disease-related biological functions, as defined by the Ingenuity Pathway Analysis database. Selected key melanoma genes are labeled with their respective HUGO gene symbols.](nihms542466f1){#F1}

![Comparison of the relative weights of within- versus between-patient differences in metastatic melanoma\
Panel a) displays the whole complexity of DNA copy number data reduced to three dimensions (D1--3) by Multidimensional Scaling (MDS). Metastases are symbolized by spheres. Recurrent metastases belonging to the same patient (A-H) are color-coded; non-recurrent, random metastasis samples, serving as controls, are grey. Panel b) shows distribution of MDS plot distances between individual metastases representing the magnitude of actual genomic differences. Statistical comparisons of MDS distances (\~genomic differences) between recurrent metastases belonging to the same, vs. different patients are shown. P-values given are derived from a standard t-test considering all possible recurrent metastasis pairs from the sample set. Panels c) and d) display similar information on whole genome RNA expression data.](nihms542466f2){#F2}

![Identification of stable individual traits conserved in recurrent metastases of a given patient through years of ongoing disease history\
On panel a), examples are shown for stable conserved copy number traits that remain characteristic for a given case of recurrent melanoma (selected examples in yellow frames). Samples belonging to the same patient are aligned horizontally and color coded (to the left). On panel b), conserved gene expression patterns, characteristic for a given case, remain stable throughout multiple recurrences and are shown using a standardized heatmap (selected examples in yellow frames). Samples are aligned vertically and color coded (top). HUGO gene symbols of selected melanoma-related genes are shown to the right.](nihms542466f3){#F3}

![Testing evolutional convergence and sequential evolution in recurrent metastatic melanomas on a global scale\
Panels a) and b) compare MDS-based distances (estimates of genomic difference) between first and last lesions of different patients experiencing multiple recurrences of melanoma. A standard t-test is applied to test whether late lesions are less different from each other than earlier ones, that is, if there is convergent evolution among individual cases of metastatic melanoma. Panels c) and d) analyze the question if subsequent recurrent recurrences (any n^th^ and n+1^th^ lesion) would be more and more distant (\~different) from the first diagnosed metastasis, implying incremental changes and thus sequential evolution of subsequent metastases.](nihms542466f4){#F4}

![Follow-up analysis of the stability of homozygous deletions in evolving recurrent metastatic melanomas\
Panel a) displays a histogram of the calculated DNA copy number values associated with every identified chromosome segment in the analyzed melanoma sample set. A blue circle marks segments accepted as homozygous deletions (−/−) considering the accuracy and statistical fidelity limits set for chromosomal segmentation. Panel b) displays the fate of these completely deleted segments in eight patients (A, B, etc.), experiencing several melanoma recurrences in a sequence (A/1, A/2, B/1, B/2, etc.), some of which are multiple synchronous recurrences (A/2a, A/2b, etc.). Yellow frames indicate selected chromosomal regions that, although completely lost at one time point of disease history (−/− = blue), months or years later re-emerged in a recurrence of the same case of cancer (−/+ = grey or +/+ = red).](nihms542466f5){#F5}
